MDM2 and cancer: The most potent compound identified was the enantiopure nutlin-3a (2, SPR IC50 = 0.09 μM, MTT IC50 = 1–2 μM in wild-type p53 cancer cell lines), which has been used in monotherapy and in combination with other anti-cancer drugs and radiation, serving as proof-of-concept for nutlins and to establish p53-MDM2 interaction as a promising and valuable target [53,54,55,56,57,58].